SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-16-593332
Filing Date
2016-05-17
Accepted
2016-05-17 17:17:37
Documents
9
Period of Report
2016-05-11
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d194360d8k.htm 8-K 20956
2 EX-3.1 d194360dex31.htm EX-3.1 29680
3 EX-3.2 d194360dex32.htm EX-3.2 95235
4 EX-4.1 d194360dex41.htm EX-4.1 28613
5 EX-99.1 d194360dex991.htm EX-99.1 5216
6 GRAPHIC g1943601a_new.jpg GRAPHIC 134706
7 GRAPHIC g1943602a.jpg GRAPHIC 3249
8 GRAPHIC g1943602b.jpg GRAPHIC 1504
9 GRAPHIC g194360ex991logo.jpg GRAPHIC 7711
  Complete submission text file 0001193125-16-593332.txt   384221
Mailing Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139
Business Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 161658505
SIC: 2835 In Vitro & In Vivo Diagnostic Substances